News Conference News ACC 2025 Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years L.A. McKeown March 30, 2025
News Conference News ACC 2025 SOUL: Oral Semaglutide Bests Usual Care in High-Risk Type 2 Diabetes Michael O'Riordan March 29, 2025